Truist Financial Corp Has $17.48 Million Holdings in Becton, Dickinson and Company $BDX

Truist Financial Corp lessened its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 46.9% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 93,400 shares of the medical instruments supplier’s stock after selling 82,564 shares during the period. Truist Financial Corp’s holdings in Becton, Dickinson and Company were worth $17,482,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in BDX. Vanguard Group Inc. increased its position in Becton, Dickinson and Company by 15.4% in the 2nd quarter. Vanguard Group Inc. now owns 32,308,749 shares of the medical instruments supplier’s stock valued at $5,565,182,000 after acquiring an additional 4,305,947 shares in the last quarter. Norges Bank acquired a new stake in shares of Becton, Dickinson and Company in the second quarter valued at approximately $653,377,000. First Eagle Investment Management LLC raised its position in Becton, Dickinson and Company by 59.2% in the 2nd quarter. First Eagle Investment Management LLC now owns 8,786,190 shares of the medical instruments supplier’s stock worth $1,513,421,000 after purchasing an additional 3,268,478 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in Becton, Dickinson and Company by 24.4% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 8,514,446 shares of the medical instruments supplier’s stock worth $1,466,613,000 after buying an additional 1,670,590 shares in the last quarter. Finally, Laurel Wealth Advisors LLC boosted its position in Becton, Dickinson and Company by 16,974.4% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 1,579,386 shares of the medical instruments supplier’s stock valued at $272,049,000 after buying an additional 1,570,136 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Trading Up 1.2%

BDX opened at $203.56 on Friday. The firm’s fifty day moving average is $198.54 and its two-hundred day moving average is $191.24. The firm has a market cap of $58.00 billion, a PE ratio of 34.92, a price-to-earnings-growth ratio of 2.22 and a beta of 0.23. Becton, Dickinson and Company has a twelve month low of $162.29 and a twelve month high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $3.96 EPS for the quarter, beating analysts’ consensus estimates of $3.92 by $0.04. The business had revenue of $5.89 billion during the quarter, compared to analysts’ expectations of $5.91 billion. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. The firm’s quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.81 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. Equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th will be issued a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.1%. The ex-dividend date is Tuesday, March 10th. Becton, Dickinson and Company’s payout ratio is 72.04%.

Becton, Dickinson and Company declared that its board has authorized a stock repurchase program on Tuesday, January 27th that permits the company to buyback $10.00 million in shares. This buyback authorization permits the medical instruments supplier to repurchase up to 0% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on BDX shares. Bank of America boosted their target price on Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a research report on Monday, January 5th. Wall Street Zen lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Morgan Stanley boosted their price target on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 2nd. Stifel Nicolaus raised their price objective on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, Becton, Dickinson and Company has a consensus rating of “Hold” and an average target price of $209.00.

Insider Buying and Selling

In other news, Director Bertram L. Scott sold 217 shares of the stock in a transaction on Friday, November 7th. The shares were sold at an average price of $176.58, for a total transaction of $38,317.86. Following the completion of the sale, the director owned 35,816 shares of the company’s stock, valued at $6,324,389.28. This represents a 0.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Michael David Garrison sold 1,610 shares of the business’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the sale, the executive vice president directly owned 12,095 shares in the company, valued at $2,509,228.70. This represents a 11.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 2,680 shares of company stock valued at $539,848. 0.40% of the stock is owned by company insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.